Neosporin

Neosporin is a United States-origin over-the-counter first-aid brand associated most closely with triple antibiotic ointment. Its classic formulation combines three topical antibacterial agents: neomycin sulfate, polymyxin B sulfate, and bacitracin zinc. The combination is intended to reduce the risk of infection in minor skin injuries such as small cuts, scrapes, abrasions, and light burns. The ointment is for external use and is generally positioned as a consumer wound-care product rather than as a treatment for serious, deep, or systemic infections. The brand entered commerce in 1952 and became one of the best-known names in American household first aid. The name Neosporin is closely associated with the generic category often called triple antibiotic ointment, although not every product carrying the Neosporin name uses exactly the same active-ingredient combination. The flagship Original Ointment contains bacitracin zinc, neomycin sulfate, and polymyxin B sulfate. Other products add ingredients intended to provide temporary pain relief, itching relief, scar-care support, or burn-related relief. The portfolio has also expanded into a double-antibiotic product made without neomycin, marketed as Simply Neosporin, to address consumers seeking a shorter ingredient list or an alternative when neomycin sensitivity is a concern. Neosporin's commercial proposition is built around convenient, familiar protection for everyday minor wounds. Its products are sold through pharmacies, mass retailers, grocery stores, online retailers, and first-aid aisles across the United States. The brand's communication generally emphasizes infection prevention, wound protection, ease of application, and the reassurance of having a recognizable medicine in a home first-aid kit. It has also used extensions containing lidocaine or pramoxine to combine antibacterial protection with temporary numbing or pain relief. The brand's product identity is based on a topical combination of agents with complementary antibacterial activity. Neomycin is an aminoglycoside antibiotic; polymyxin B is active against a range of Gram-negative organisms; and bacitracin is primarily active against many Gram-positive organisms. Together, the ingredients provide relatively broad topical coverage, but they are not free of limitations. Neomycin and bacitracin are recognized causes of allergic contact dermatitis in some users, and labels advise consumers to stop use and seek medical advice if irritation, rash, or worsening symptoms occur. The products are intended for minor wounds and are not substitutes for professional care when an injury is extensive, infected, deep, or otherwise serious. Neosporin also sits within a broader debate about routine topical antibiotic use. Dermatology literature has documented allergic reactions to ingredients such as neomycin and bacitracin, while microbiological research has raised questions about whether repeated or widespread exposure to topical antibiotics could contribute to selection for resistant organisms. These issues have influenced the development and marketing of alternative formulations, including double-antibiotic products without neomycin, and have made ingredient transparency an important part of the brand's consumer information. Historically associated with Johnson & Johnson's consumer-health business, Neosporin became part of Kenvue's portfolio when that business was separated from Johnson & Johnson. Kenvue became an independent public company in August 2023. The brand remains active and continues to be marketed as part of Kenvue's consumer-health and first-aid portfolio. Its long commercial history, strong household recognition, and broad retail availability make it one of the most prominent topical antibiotic brands in the American market.

Neosporin developed from the postwar expansion of topical antibiotic medicines into consumer first aid. The brand is associated with a three-antibiotic combination consisting of neomycin, polymyxin B, and bacitracin. The individual antibiotics were developed during the rapid growth of antimicrobial research in the 1940s and early 1950s, and their combination provided a convenient topical preparation for reducing infection risk after minor skin trauma. The Neosporin name was first used in commerce in August 1952. A United States patent covering the antibiotic ointment was issued in August 1952, and the Neosporin trademark application was filed in October of that year. The mark was federally registered in 1953. During the following decades, Neosporin became closely identified with the home medicine cabinet and the first-aid treatment of everyday cuts, scrapes, abrasions, and minor burns. The brand's central product proposition was the combination of three antibiotics in a petroleum-based ointment. Neomycin contributed activity against a range of Gram-positive and Gram-negative bacteria, polymyxin B offered activity particularly against many Gram-negative organisms, and bacitracin contributed activity against many Gram-positive organisms. This combination was commonly described as triple antibiotic ointment, a generic category that includes products sold under several different brand names. Over time, Neosporin expanded beyond its original ointment format. Product variations were introduced with ingredients intended to provide temporary pain relief, itching relief, scar-care benefits, or additional support for burns and other minor injuries. Some products used pramoxine or lidocaine as topical anesthetic ingredients. The brand also introduced a double-antibiotic formulation without neomycin, responding to consumer interest in fewer ingredients and the fact that neomycin can cause allergic contact dermatitis in susceptible individuals. The product category has faced continuing medical and regulatory scrutiny. Topical antibiotics can cause irritation or allergic reactions, and published dermatology research has identified both neomycin and bacitracin as important sensitizers. Because of this, modern product labeling emphasizes external use, limited use on minor wounds, avoidance of the eyes and large body areas, and discontinuation if a rash or other adverse reaction develops. Research has also examined the possibility that repeated exposure to topical antimicrobial agents may contribute to antimicrobial resistance. These findings have not amounted to a general Neosporin recall, but they have shaped professional discussion about when topical antibiotics are appropriate and encouraged the use of simpler wound-care approaches or non-neomycin alternatives in some situations. For most of its corporate history, Neosporin was connected with Johnson & Johnson's consumer-health operations. Johnson & Johnson began separating that consumer-health business in the early 2020s, creating Kenvue as a dedicated consumer-health company. Kenvue completed the final separation from Johnson & Johnson on August 23, 2023, and Neosporin became part of Kenvue's independent brand portfolio. Kenvue's United States operating entity was later renamed Kenvue Brands LLC, while the parent company continued operating as Kenvue Inc. In 2025, Kenvue moved its global headquarters from Skillman to Summit, New Jersey. Neosporin remains an active brand marketed primarily through United States retail and e-commerce channels, with related products also available in Canada. Its enduring strength comes from the combination of a short, memorable name, longstanding household familiarity, broad retail distribution, and a product proposition tied to a common consumer need: protecting minor wounds during everyday first aid.

• 2025

  Kenvue moves global headquarters to Summit

  [8]Kenvue headquarters opening in Summit, New Jerseykenvue.com

  Kenvue officially opens its global headquarters in Summit, New Jersey, replacing Skillman as its corporate headquarters location.

• 2023

  Kenvue becomes independent from Johnson & Johnson

  [6]Kenvue becomes a fully independent companykenvue.com

  Kenvue completes its separation from Johnson & Johnson on August 23, 2023, taking Neosporin into its independent consumer-health portfolio.

• 2023

  Updated Original Ointment label published

  [4]Neosporin Original Ointment DailyMed labeldailymed.nlm.nih.gov

  A DailyMed label identifies the active ingredients and formulation details for Kenvue's Neosporin Original Ointment.

• 2011

  Study examines topical-antibiotic resistance

  [9]Antimicrobial Ointments and Methicillin-Resistant Staphylococcus aureus USA300stacks.cdc.gov

  Research published by the CDC's Emerging Infectious Diseases journal examines resistance to bacitracin and neomycin in USA300 MRSA isolates and discusses possible selection pressure from over-the-counter antimicrobial ointments.

• 1953

  Neosporin trademark registered

  [5]Neosporin trademark recordtrademarks.justia.com

  The Neosporin trademark is registered in the United States on March 31, 1953.

• 1952

  Neosporin first used in commerce

  [5]Neosporin trademark recordtrademarks.justia.com

  The Neosporin mark is first used in United States commerce on August 26, 1952, for a mixture of antibiotics used in topical medical applications.

• 1952

  United States patent associated with the ointment

  [1]Neomycin/polymyxin B/bacitracinen.wikipedia.org

  A United States patent covering the antibiotic ointment is recorded in August 1952, establishing an early legal milestone for the product technology.

• 1952

  Neosporin trademark application filed

  [5]Neosporin trademark recordtrademarks.justia.com

  The Neosporin trademark application is filed on October 9, 1952.

• 1949

  Neomycin is discovered

  [1]Neomycin/polymyxin B/bacitracinen.wikipedia.org

  Neomycin, one of the active antibiotics later used in Neosporin, is identified during the expansion of postwar antibiotic research.

Over-the-counter first aid and topical wound-care brand focused on infection prevention, everyday minor-injury protection, and optional pain, itch, scar, burn, and lip-care benefits.

• Topical antibiotic ointment · 1952

  NEOSPORIN Original Triple Antibiotic Ointment

  The flagship Neosporin formulation contains bacitracin zinc, neomycin sulfate, and polymyxin B sulfate in an ointment base. It is marketed for infection protection in minor cuts, scrapes, and light burns. The product represents the classic triple-antibiotic identity associated with the brand and is sold as an over-the-counter first-aid medicine. Label directions limit its intended use to minor external wounds and include warnings concerning allergic reactions, irritation, and inappropriate use on serious injuries.

• Pain-relief topical antibiotic ointment

  NEOSPORIN + Pain Relief Antibiotic Ointment

  This variant combines the brand's topical antibiotic approach with pramoxine hydrochloride, a local anesthetic used to temporarily relieve pain and discomfort associated with minor cuts, scrapes, and burns. The product is positioned as a convenient two-benefit first-aid treatment: protection against infection-causing bacteria and temporary soothing of painful minor wounds. Its active ingredients and formulation can differ from the Original Ointment, so product-specific labeling is important.

• Lidocaine-containing antibiotic ointment

  NEOSPORIN + Lidocaine First Aid Antibiotic Ointment

  The lidocaine variant is designed for consumers seeking antibiotic wound protection together with a numbing effect. It contains lidocaine as a local anesthetic and is marketed for minor cuts, scrapes, and burns. The product extends Neosporin beyond infection prevention into symptom relief while retaining the brand's first-aid positioning. The manufacturer states that lidocaine numbs the area and may take approximately 30 to 60 minutes to produce its effect.

• Neomycin-free double antibiotic ointment

  SIMPLY NEOSPORIN Double Antibiotic Ointment

  Simply Neosporin uses bacitracin zinc and polymyxin B sulfate rather than the three-antibiotic Original Ointment formula. The product is promoted as a three-ingredient ointment made with the two antibiotics and petrolatum, without neomycin, preservatives, or parabens. It is intended to provide infection protection for minor wounds while offering an option for consumers concerned about neomycin sensitivity or who prefer a shorter ingredient list.

• Multi-benefit topical antibiotic ointment

  NEOSPORIN + Pain, Itch, Scar

  This product is positioned as a multi-benefit version of the brand's topical antibiotic ointment. It combines infection protection with claims related to temporary pain and itch relief and helping minimize the appearance of scars associated with minor wounds. It is marketed for everyday first aid and is intended to be used according to product-specific directions rather than as a general treatment for established or serious infections.

• Burn-relief topical antibiotic ointment

  NEOSPORIN Burn Relief Antibiotic Ointment

  The Burn Relief product is tailored to minor burn first aid. It combines topical antibiotic protection with an ingredient or formulation intended to help relieve burn discomfort. The product fits Neosporin's broader strategy of adapting its familiar wound-care platform to specific minor-injury occasions while preserving the brand's emphasis on external use, infection prevention, and household first-aid convenience.

• Lip-care treatment

  NEOSPORIN LIP HEALTH Overnight Renewal Therapy

  Neosporin Lip Health Overnight Renewal Therapy extends the brand into non-antibiotic lip care. It is marketed for dry and chapped lips and is positioned as an overnight treatment rather than as a wound antibiotic. The product demonstrates the brand's expansion from traditional minor-wound care into adjacent personal-care needs while retaining the Neosporin name and its association with protective everyday care.

• 2025

  Kenvue headquarters relocationStrategy

  Background

  Kenvue planned a new global headquarters and research hub in Summit, New Jersey, as part of its development as an independent consumer-health company.

  Action taken

  Kenvue moved its global headquarters from Skillman to Summit and officially opened the new campus in March 2025.

  Aftermath

  Summit became the current headquarters location for Kenvue, the company responsible for the Neosporin brand.

  Source

• 2024

  United States operating entity renamed Kenvue Brands LLCStrategy

  Background

  Following the separation from Johnson & Johnson, Kenvue updated the legal names of certain operating subsidiaries to reflect its independent corporate identity.

  Action taken

  Effective October 28, 2024, Johnson & Johnson Consumer Inc. in the United States was renamed Kenvue Brands LLC.

  Aftermath

  The legal-entity change did not alter the Neosporin brand name or its consumer-facing product positioning.

  Source

• 2023

  Transfer of Neosporin into KenvueM&A

  Background

  Johnson & Johnson separated its consumer-health business into Kenvue, a dedicated consumer-health company whose portfolio included Neosporin.

  Action taken

  Kenvue completed the final separation from Johnson & Johnson on August 23, 2023, and assumed responsibility for the consumer-health portfolio containing Neosporin.

  Aftermath

  Neosporin continued as an active Kenvue brand. The change affected corporate ownership and management structure rather than the brand's core consumer positioning.

  Source

• 2023

  Neomycin-free Simply Neosporin formulationProduct launch

  Background

  Neomycin is a known contact allergen for some users, creating demand for topical antibiotic alternatives that omit the ingredient.

  Action taken

  Neosporin introduced Simply Neosporin, a double-antibiotic ointment based on bacitracin zinc and polymyxin B sulfate without neomycin, preservatives, or parabens.

  Aftermath

  The brand broadened its portfolio to include a formulation aimed at consumers seeking fewer ingredients or an option suitable for those concerned about neomycin sensitivity.

  Source

• 2025

  Kenvue opens new global headquarters in Summit, New Jersey[8]Kenvue headquarters opening in Summit, New Jerseykenvue.com

  Other

  Kenvue officially opened its new global headquarters in Summit, New Jersey. The relocation established Summit as the current corporate headquarters for the company that owns and markets Neosporin.

• 2023

  Neosporin brand becomes part of Kenvue's independent consumer-health portfolio[6]Kenvue becomes a fully independent companykenvue.com

  M&A · Other

  Kenvue completed its separation from Johnson & Johnson on August 23, 2023. Neosporin was included among the established consumer-health brands transferred into Kenvue's portfolio.

• 2023

  Updated Neosporin Original Ointment labeling identifies the three active antibiotics[4]Neosporin Original Ointment DailyMed labeldailymed.nlm.nih.gov

  Other · Product generation

  The updated United States label for Neosporin Original Ointment identifies bacitracin zinc, neomycin sulfate, and polymyxin B sulfate as the active ingredients and describes the product as a topical first-aid antibiotic ointment.

• 2011

  Research raises questions about resistance associated with over-the-counter antimicrobial ointments[9]Antimicrobial Ointments and Methicillin-Resistant Staphylococcus aureus USA300stacks.cdc.gov

  Other · Regulation

  A study published in Emerging Infectious Diseases reported resistance to bacitracin and neomycin among tested USA300 methicillin-resistant Staphylococcus aureus isolates and suggested that use of over-the-counter antimicrobial products could exert selective pressure. The study concerned antimicrobial ointments as a category and was not a product recall or regulatory finding against Neosporin specifically.

1. 1Neomycin/polymyxin B/bacitracinen.wikipedia.org
2. 2Neosporin official product catalogneosporin.com
3. 3What Is NEOSPORIN and What Is It Used For?neosporin.com
4. 4Neosporin Original Ointment DailyMed labeldailymed.nlm.nih.gov
5. 5Neosporin trademark recordtrademarks.justia.com
6. 6Kenvue becomes a fully independent companykenvue.com
7. 7Kenvue headquarters informationinvestors.kenvue.com
8. 8Kenvue headquarters opening in Summit, New Jerseykenvue.com
9. 9Antimicrobial Ointments and Methicillin-Resistant Staphylococcus aureus USA300stacks.cdc.gov
10. 10Bacitracin: a unique topical antibiotic sensitizerpubmed.ncbi.nlm.nih.gov
11. 11Neomycin-free Simply Neosporin formulationneosporin.com
12. 12United States operating entity renamed Kenvue Brands LLCkenvue.com